Related Experiment Video

Updated: Aug 20, 2026

RhoC GTPase Activation Assay
09:58

RhoC GTPase Activation Assay

Published on: August 22, 2010

Targeting Ras and Rho GTPases as opportunities for cancer therapeutics

Katharine Walker1, Michael F Olson

  • 1The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.

Current Opinion in Genetics & Development
|January 22, 2005
PubMed

Insights

Ras and Rho GTPases are key regulators in cancer development, influencing cell growth, survival, and spread. Their critical roles make them promising targets for novel cancer therapies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Ras and Rho GTPases are crucial regulators of intracellular signaling pathways.
  • Dysregulation of these GTPases contributes significantly to cancer initiation and progression.
  • They influence multiple hallmarks of cancer, including proliferation, survival, and metastasis.

Purpose of the Study:

  • To highlight the multifaceted roles of Ras and Rho GTPases in cancer.
  • To underscore their importance in promoting malignant phenotypes.
  • To identify them as attractive targets for cancer therapeutic development.

Main Methods:

  • This review synthesizes existing research on Ras and Rho GTPase signaling in cancer.
  • It analyzes their involvement in key cellular processes driving malignancy.
  • No new experimental data were generated; this is a review-based analysis.

Main Results:

  • Ras and Rho GTPases subvert normal cellular signaling to promote cancer.
  • They drive critical aspects of the malignant phenotype, including cell cycle progression, apoptosis resistance, angiogenesis, motility, invasion, and metastasis.
  • Their widespread involvement across multiple cancer-driving mechanisms is confirmed.

Conclusions:

  • Ras and Rho GTPases are central players in oncogenesis.
  • Targeting these GTPases holds significant therapeutic potential for various cancers.
  • Further research into their specific roles and inhibition strategies is warranted for effective cancer treatment.

More Related Videos

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...